Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States

Vaccine

Volumn 31, Issue 37, 2013, Pages 3899-3905

  Chesson, Harrell W ^a   Ekwueme, Donatus U ^b   Saraiya, Mona ^b   Dunne, Eileen F ^a   Markowitz, Lauri E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

Cervical neoplasms; Genital warts; Models; Papillomavirus; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONDYLOMA ACUMINATUM; FEMALE; GENDER; HUMAN; HUMAN PAPILLOMAVIRUS VACCINATION; MALE; PRIORITY JOURNAL; SCHOOL CHILD; UNITED STATES; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION;

CERVICAL NEOPLASMS; GENITAL WARTS; MODELS; PAPILLOMAVIRUS; VACCINATION;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; CONDYLOMATA ACUMINATA; FEMALE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; HUMANS; IMMUNIZATION PROGRAMS; MALE; MODELS, THEORETICAL; PAPILLOMAVIRUS VACCINES; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84881542793     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.050     Document Type: Article

References (36)

1. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56(RR-2):1-24.
2. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., Garnett G.P. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006, 3(5):e138.
3. Garnett G.P., Kim J.J., French K., Goldie S.J. Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006, 24(Suppl. 3):S178-S186.
4. Kohli M., Ferko N., Martin A., Franco E.L., Jenkins D., Gallivan S., et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 2007, 96(1):143-150.
5. Brisson M., Van D.V., De W.P., Boily M.C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007, 25(July (20)):5399-5408.
6. Chesson H.W., Ekwueme D.U., Saraiya M., Dunne E.F., Markowitz L.E. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011, 29(October (26)):8443-8450.
7. Elbasha E.H., Dasbach E.J., Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007, 13(1):28-41.
8. Taira A.V., Neukermans C.P., Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004, 10(November (11)):1915-1923.
9. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004, 96(8):604-615.
10. Wong C.A., Saraiya M., Hariri S., Eckert L., Howlett R.I., Markowitz L.E., et al. Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. Vaccine 2011, 29(5):878-885.
11. Markowitz L.E., Hariri S., Unger E.R., Saraiya M., Datta S.D., Dunne E.F. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010, 28(30):4731-4737.
12. Bauer H.M., Wright G., Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-010. Am J Public Health 2012, 102(5):833-835.
13. Flagg E.W., Schwartz R., Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-010: potential impact of HPV vaccination. Am J Public Health 2013, e1-e8. 10.2105/AJPH.2012.301182.
14. Fairley C.K., Hocking J.S., Gurrin L.C., Chen M.Y., Donovan B., Bradshaw C. Rapid decline in presentations for genital warts after the implementation of a national quadrivalent human papillomavirus vaccination program for young women. Sex Transm Infect 2009, 85:499-502.
15. Read T.R., Hocking J.S., Chen M.Y., Donovan B., Bradshaw C.S., Fairley C.K. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011, 87(7):544-547.
16. Donovan B., Franklin N., Guy R., Grulich A.E., Regan D.G., Ali H., et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011, 11(1):39-44.
17. Brotherton J.M., Fridman M., May C.L., Chappell G., Saville A.M., Gertig D.M. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377(9783):2085-2092.
18. Hoy T., Singhal P.K., Willey V.J., Insinga R.P. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin 2009, 25(10):2343-2351.
19. Future II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(19):1915-1927.
20. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6(5):271-278.
21. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(19):1928-1943.
22. Munoz N., Manalastas R., Pitisuttithum P., Tresukosol D., Monsonego J., Ault K., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009, 373(9679):1949-1957.
23. Palefsky J., Giuliano A. Efficacy of the quadrivalent HPV vaccine against HPV 6/11/16/18-related genital infection in young men 2008, European Research Organization on Genital Infection and Neoplasia (EUROGIN) 2008, Nice, France.
24. Giuliano A.R., Palefsky J., Goldstone S., Moreira E.D., Penny M.E., Arand C., et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011, 364(5):401-411.
25. Dorell C., Stokley S., Yankey D., Jeyarajah J., MacNeil J., Markowitz L. National and state vaccination coverage among adolescents aged 13 through 17 years - United States, 2011. MMWR Morb Mortal Wkly Rep 2012, 61(34):671-677.
26. Gertig D.M., Brotherton J.M., Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011, 8(2):171-178.
27. Jit M., Chapman R., Hughes O., Choi Y.H. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. Br Med J 2011, 343:d5775.
28. Kessels S.J., Marshall H.S., Watson M., Braunack-Mayer A.J., Reuzel R., Tooher R.L. Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine 2012, 30(24):3546-3556.
29. Centers for Disease Control Prevention Recommendations on the use of quadrivalent human papillomavirus vaccine in males - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011, 60(50):1705-1708.
30. Chesson H.W., Flagg E.W., Koutsky L., Hsu K., Unger E.R., Shlay J.C., et al. Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States. Vaccine 2013, doi:10.1016/j.vaccine.2013.04.051.
31. Markowitz L.E., Hariri S., Lin C., Dunne E.F., Steinau M., McQuillan G., et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013, [Epub ahead of print].
32. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103(19):1444-1451.
33. Kim J.J., Goldie S.J. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. Br Med J 2009, 339:b3884.
34. Elbasha E.H., Dasbach E.J. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010, 28(42):6858-6867.
35. Jit M., Choi Y.H., Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. Br Med J 2008, 337:a769.
36. Van de Velde N., Brisson M., Boily M.C. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine 2010, 28(33):5473-5484.